清髓性单倍体骨髓移植联合移植后环磷酰胺治疗儿童急性白血病的前瞻性PTCTC试验
儿童移植与细胞治疗联盟(PTCTC)开展首个多中心试验,9个中心为32例高危急性白血病或MDS的儿童及年轻成人行清髓性单倍体骨髓移植联合移植后环磷酰胺。180天移植相关死亡率为0%,2-4级急性GVHD未发生,1年中度至重度慢性GVHD累积发生率为4%,1年复发累积发生率为32%,2年总生存率和无事件生存率分别为73%和64%。
要点
- 180天移植相关死亡率为0%,未发生3-4级急性GVHD。
- 1年中度至重度慢性GVHD累积发生率为4%。
- 1年复发累积发生率为32%,移植前MRD阳性者复发更多。
核心结论
- 该试验未发生移植相关死亡或重度急性GVHD,慢性GVHD发生率低,复发率和生存率良好。
- 该成功的先导试验已促成儿童肿瘤协作组开展3期试验,比较清髓性单倍体骨髓移植与HLA相合无关供者骨髓移植。
研究设计与样本
- 儿童移植与细胞治疗联盟(PTCTC)开展的多中心前瞻性试验,9个中心为32例高危急性白血病或MDS的儿童及年轻成人行清髓性单倍体骨髓移植联合移植后环磷酰胺、吗替麦考酚酯和他克莫司。
- 患者中位年龄12岁,诊断包括AML 15例、ALL 11例、混合谱系白血病1例和MDS 5例。
- 该试验在www.clinicaltrials.gov注册,注册号为NCT02120157。
主要发现
- 180天移植相关死亡率为0%。
- 100天2级急性GVHD累积发生率为13%,未发生3-4级急性GVHD。
- 1年中度至重度慢性GVHD累积发生率为4%。
- 27例(84%)患者实现供者植入;原发植入失败包括3例接受了次优骨髓移植物,均在第二次移植后成功植入。
- 1年复发累积发生率为32%,移植前MRD阳性者较MRD阴性者复发更多;1年和2年总生存率分别为77%和73%,1年和2年无事件生存率分别为68%和64%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Promising results have been reported for adult patients with high-risk hematologic malignancies undergoing haploidentical bone marrow transplant (haploBMT) with posttransplant cyclophosphamide (PTCy). To our knowledge, we report results from the first multicenter trial for pediatric and young adult patients with high-risk acute leukemias and myelodysplastic syndrome (MDS) in the Pediatric Transplantation and Cellular Therapy Consortium. Nine centers performed transplants in 32 patients having acute leukemias or MDS, with myeloablative conditioning (MAC), haploBMT with PTCy, mycophenolate mofetil, and tacrolimus. The median patient age was 12 years. Diagnoses included AML (15), ALL (11), mixed-lineage leukemia (1), and MDS (5). Transplant-related mortality (TRM) at 180 days was 0%. The cumulative incidence (CuI) of grade 2 acute graft-versus-host disease (aGVHD) on day 100 was 13%. No patients developed grades 3-4 aGVHD. The CuI of moderate-to-severe chronic GVHD (cGVHD) at 1 year was 4%. Donor engraftment occurred in 27 patients (84%). Primary graft failures included 3 patients who received suboptimal bone marrow grafts; all successfully engrafted after second transplants. The CuI of relapse at 1 year was 32%, with more relapse among patients MRD positive pre-BMT vs MRD negative. Overall survival rates at 1 and 2 years were 77% and 73%, and event-free survival rate at 1 and 2 years were 68% and 64%. There was no TRM or severe aGVHD, low cGVHD, and favorable relapse and survival rates. This successful pilot trial has led to a phase 3 trial comparing MAC haploBMT vs HLA-matched unrelated donor BMT in the Children's Oncology Group. This trial was registered at www.clinicaltrials.gov as #NCT02120157.
引用
- Fierro-Pineda JC, Tsai HL, Blackford A, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023. PMID: 37257193. doi:10.1182/bloodadvances.2023010281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。